Riders · Board of Pharmacy · Article VIII: Regulatory

Prescription Monitoring Program

Rider 4 in the 2026-27 Act, page VIII-44

Through the session

  1. 2024-25 Act In current law rider 5
  2. Introduced (Senate) Amended rider 4
  3. Introduced (House) Amended rider 4
  4. Senate substitute Amended rider 4
  5. House substitute Amended rider 4
  6. House passed Unchanged rider 4
  7. Conference Amended rider 4
  8. 2026-27 Act Unchanged rider 4

Pick any two steps to compare their wording.

What changed in the text

House passed → Conference: 2 passages changed.

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to implement maintain Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections. Included in amounts appropriated above is $225,000 in fiscal year 2026 and $150,000 in fiscal year 2027 from the Opioid Abatement Account No. 5189 to implement system enhancements related to the Prescription Monitoring Program, including an alert mechanism capable of identifying lapses in treatment for patients prescribed buprenorphine or other medications for the treatment of opioid use disorder.

Removed words are struck through; added words are underlined. Sources: House passed · Conference.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium 5 First version — Page VIII-39
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) 4 was 5 Amended — Page VIII-42
Introduced (House)House Bill 1 as introduced (LBB recommended, House) 4 was 5 Amended — Page VIII-42
Senate substituteCommittee Substitute for Senate Bill 1 4 Amended Amended Page VIII-39
House substituteHouse Committee Substitute for Senate Bill 1 4 Amended Amended Page VIII-39
House passedSenate Bill 1 as passed the second house 4 Unchanged Amended Page VIII-39
ConferenceConference Committee Report for Senate Bill 1 4 Amended Amended Page VIII-44
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 4 Unchanged Amended Page VIII-44
Full text of each wording

Conference, 2026-27 Act

Source, page VIII-44

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to maintain Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.

House substitute, House passed

Source, page VIII-39

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections. Included in amounts appropriated above is $225,000 in fiscal year 2026 and $150,000 in fiscal year 2027 from the Opioid Abatement Account No. 5189 to implement system enhancements related to the Prescription Monitoring Program, including an alert mechanism capable of identifying lapses in treatment for patients prescribed buprenorphine or other medications for the treatment of opioid use disorder.

Senate substitute

Source, page VIII-39

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2026 and $3,700,750 in fiscal year 2027 from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.

Introduced (Senate), Introduced (House)

Source, page VIII-42

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription

Monitoring Program, include $3,700,750 in fiscal year 202           6 and $3,700,750 in fiscal year 202     7

from the General Revenue Fund to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Section 2, Appropriations Limited to Revenue Collections.

2024-25 Act

Source, page VIII-39

Prescription Monitoring Program. Amounts appropriated above in Strategy B.1.3, Prescription Monitoring Program, include $3,700,750 in fiscal year 2024 and $3,700,750 in fiscal year 2025 in General Revenue Funds to implement Narxcare and Statewide Integration. These amounts are exempt from Article VIII, Special Provisions Relating to all Regulatory Agencies, Sec. 2, Appropriations Limited to Revenue Collections.